AstraZeneca Announces Results from a Sub-Analysis of PLATO; Cell Therapeutics Makes Progress with Lymphoma Drug Print
By Staff and Wire Reports   
Monday, 24 September 2012 18:26
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 24, 2012.

AstraZeneca (NYSE: AZN)
announced results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results of this analysis suggest the overall findings from the PLATO study of a greater reduction in thrombotic cardiovascular (CV) events with BRILINTA® (ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. These data are now published in the September print and online issues of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology 2011 meeting.

This PLATO age sub-analysis is important because approximately 33% of all ACS episodes occur in patients over 75 years.

Elderly patients with ACS are at high risk for recurrent ischemic events and treatment-related complications, stated James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, and Vice President for Global Medical Affairs. This PLATO sub-analysis suggests that the clinical benefits of BRILINTA vs. clopidogrel on thrombotic CV events were not significantly affected by age, and were similar in patients 75 years of age and older and younger patients.

BRILINTA is indicated to reduce the rate of thrombotic CV events in patients with ACS (unstable angina [UA], nonST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). In PLATO, BRILINTA has been shown to reduce the rate of a combined end point of CV death, myocardial infarction (MI), or stroke compared to clopidogrel. In PLATO, the difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate of stent thrombosis.


The phase 1 study of Cell Therapeutics' (NASDAQ:CTIC) highly selective oral JAK2 inhibitor pacritinib showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed or refractory lymphoma.

"This phase 1 study suggests the potential therapeutic value of targeting the JAK2 pathway in lymphomas with encouraging single agent activity demonstrated despite the extensive degree of prior therapy and refractory nature of the disease among the patients who were enrolled in this trial," noted Chief Medical Officer Steven E. Benner.

Pacritinib is an oral, once a day, tyrosine kinase inhibitor that works against mutations in kinases that are directly related to the development of a variety of blood-related cancers including Myeloproliferative disorders, leukemia and lymphoma. The drug company noted that pacritinib has demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis and a phase 3 study is planned in this disease.

Lymphoma is a cancer of the white blood cells, namely lymphocytes, which constitute the lymphatic system. Lymphoma occurs when lymphocytes grow abnormally. The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma.

The study reported Monday enrolled 35 patients with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma. Patients had relapsed following a median of five prior therapies.

The results of the latest study come after Cell Therapeutics in May won conditional authorization to market Pixvuri--its treatment for non-Hodgkin B-cell lymphomas--in the European Union.

The approval represented a victory for Cell Therapeutics, which in January had to withdraw Pixvuri's new drug application in the U.S. The drug maker said the delay would give it more time to prepare for a second U.S. Food and Drug Administration committee review.

Last year, an FDA panel unanimously rejected Pixvuri, saying there wasn't enough clinical evidence to show the drug worked.

Shares closed at $2.72 Friday and were inactive premarket. The stock has fallen 53% so far this year.

Also Monday:

Amarantus BioSciences, Inc. (OTCBB: AMBS)
, a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson's disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research.

Cardium Therapeutics (NYSE MKT: CXM)
today announced that Christopher J. Reinhard, Chairman & CEO will present at the BioX Noble Financial Life Sciences Exposition being held at the University of Connecticut, Stamford Campus on September 24 – 25, 2012.

Cellceutix Corporation (OTCBB: CTIX)
(the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, is pleased to update shareholders on the status of clinical trials for the Company's novel anti-cancer drug, Kevetrin™, at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center.

("CONMED") today announced the successful completion of the tender offer by its wholly-owned subsidiary, Arrow Merger Corporation ("Merger Sub"), for all of the outstanding shares of common stock of Viking Systems, Inc. (OTCBB: VKNG) (OTCQB: VKNG) ("Viking") at a price of $0.27 per share, net to the seller in cash (less any required withholding taxes and without interest).

Daxor Corporation (NYSE MKT: DXR)
, an investment company with medical instrumentation and biotechnology operations, announced the presentation of a study entitled "Masked Polycythemia in Patients with Heart Failure and a Preserved Ejection Fraction: an underappreciated phenotype?" by Sahadeo D. Ramnauth, M.D., Sergio Teruya, M.D., Stephen Helmke, RDCS, and Matthew S. Maurer, M.D. at the Division of Cardiology, Columbia University Medical Center in New York.

Dyadic International, Inc. (OTC Pink: DYAI)
, a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today the results of its cooperation with SEKAB E-Technology on verifying effective enzymes for the degradation of cellulose into fermentable sugars as part of the recently concluded DISCO research project.

Dyadic International, Inc. (OTC Pink: DYAI)
, a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,268,585 entitled, "Transformation System in the Field of Filamentous Fungal Hosts"by the United States Patent and Trademark Office ("USPTO").

MMRGlobal, Inc. (OTCBB: MMRF)
("MMR") today announced that the Company received another Notice of Allowance, or NOA.

Neptune Technologies & Bioressources Inc. (TSX:NTB) (NASDAQ:NEPT)
, a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares.

Neuralstem, Inc. (NYSE MKT: CUR)
announced that President and CEO Richard Garr will present at the 2012 Aegis Healthcare Conference on Friday, September 28 at 10:00 a.m. PT.

Response Biomedical Corp. (TSX:RBM)(OTCBB:RPBIF)
(the "Company" or "Response"), announced today the completion of the consolidation of issued and outstanding common shares of the Company (the "Common Shares") on the basis of every twenty (20) Common Shares being consolidated into one (1) Common Share (the "Consolidation").

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT)
today announced the appointment of John P. Hamill as Senior Vice President & Chief Financial Officer effective today.  

World Health Energy Holdings, Inc. (PINKSHEETS: WHEN)
, a public holding company developing joint venture partnerships for algae production for biodiesel and commercial fish food, announced Today that Initial testing of the WHEN Algae system for Water Purification showed a reduction in Saline levels system and that a Research report was released by Stock Legends.

World Health Energy Holdings, Inc. (PINKSHEETS: WHEN)
, a public holding company developing joint venture partnerships for algae production for biodiesel and commercial fish food, announced Today that Stock Legends Radio is featuring the WHEN New Business development manager CJ Lieberman on its upcoming radio show.

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY)
(the "Company"), a biopharmaceutical development company, announced today that it has approved a change in the ratio of its American Depositary Receipts ("ADRs") to ordinary shares in order to facilitate the Company's qualification for listing on the NASDAQ Capital Market.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus